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Society
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osting by E
ing by ElsAbstract Aim of the work: To evaluate the diagnostic values of the hepatic ADC calculated with
diffusion-weighted MRI for quantiﬁcation of the hepatic ﬁbrosis in patients with chronic viral hep-
atitis.
Subjects and methods: Thirty-eight chronic viral hepatitis C patients with similar control group
were examined by 1.5 Tesla MR scanner with diffusion gradient encoding in three orthogonal direc-
tions at b values of (300, 500, 700, and 1000 s/mm2). They were correlated to biopsy ﬁnding and
graded according to Ishak scoring system. Hepatic ADC values were measured for both patients
and control groups.
Results: The best correlation between ADC values and biopsy were seen at b values 300, 700, and
1000 s/mm2, which showed high sensitivity, speciﬁcity, positive, and negative predictive values, with
lesser correlation were obtained at b values of 500 s/mm2. Cut off values between different grades of
ﬁbrosis were calculated and presented in the text.
Conclusion: ADC measured with DWI is a reliable non-invasive technique for quantiﬁcation of
liver ﬁbrosis, and could replace liver biopsy in certain cases.
 2011 Egyptian Society of Radiology and Nuclear Medicine. Production and hosting by Elsevier B.V.
All rights reserved.(A.A. EL-Hamid).
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Hepatic ﬁbrosis and cirrhosis are important causes of morbid-
ity, mortality, and increasing health care costs (1).
In the stage of cirrhosis where the liver is still compensating,
and particularly in cases secondary to hepatitis C virus infec-
tion, interferon treatment can help prolong sufﬁcient liver
function (2). Thus, it is important to evaluate disease severity
and to deﬁne the stage of cirrhosis, indication for antiviral
therapy, and to follow the disease progression carefully (3,4).
Histopathologic ﬁndings obtained at liver biopsy are used to
assess degree of ﬁbrosis stage (5,2); many classiﬁcations are
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ﬂammatory changes; as Ishak’s scoring and Batts–Ludwig
classiﬁcations (3,6).
According to Batts–Ludwig classiﬁcation, staging is used to
evaluate the degree of ﬁbrosis; stage 0, no ﬁbrosis; stage 1, por-
tal ﬁbrosis; stage 2, periportal ﬁbrosis; stage 3, septal ﬁbrosis;
and stage 4, cirrhosis. Grading of activity refers to degree of
hepatocellular necroinﬂammatory activity: grade 1, no activ-
ity; grade 2, minimal; grade 3, moderate, where grade 4, severe
activity (3,6,7).
Liver biopsy, although it is a relatively safe procedure when
performed by experienced clinicians, it is not risk free (8,9). It
is prone to inter-observer variability and underestimation of
disease severity due to sampling errors (10,11), and it has a
poor acceptance by the patient (3).
Thus development of noninvasive imaging methods would
reduce biopsy-related risks, and hence potentially eliminate
sampling errors and enable global liver assessment (12). These
capabilities would enable serial follow up of patients, docu-
mentation of temporal changes, and assessment of therapy re-
sponse; provide direct beneﬁts to patients and serve as a
powerful research tool for therapy development (13).
Sonography is an operator dependent and less accurate for
detecting the presence or extent of ﬁbrosis (14,15). Doppler
indices of the hepatic vasculature are also not reproducibly
very reliable in detecting and grading ﬁbrosis (14,16). Con-
trast-enhanced sonography using microbubbles has been
reported to be helpful in differentiating the severity of ﬁbrosis
in patients with hepatitis C, with signiﬁcantly lower hepatic
vein transit times in cirrhotic patients than in those with milder
ﬁbrosis, but this technique requires multi-center validation
(14,17).
Neither CT nor conventional MRI has been shown to have
high sensitivity for early ﬁbrosis (14); however, noninvasive
diagnosis with double contrast material-enhanced MR imag-
ing can detect advanced hepatic ﬁbrosis (14,12).
With diffusion-weighted MRI (DWI), water diffusion is
quantiﬁed by the calculation of the apparent diffusion coefﬁ-
cient (ADC), which can be used for in vivo quantiﬁcation of
the combined effects of capillary perfusion and diffusion
(13,3,18).
The study aims to evaluate the diagnostic values of the
hepatic ADC calculated with diffusion-weighted MRI for
quantiﬁcation of the hepatic ﬁbrosis in patients with chronic
viral hepatitis.2. Subjects and methods
Eligible 38 chronic viral hepatitis C patients with similar con-
trol groups were included in our case-control study; sampled in
a simple random manner, where referred from hepatology out-
clinic and studied in MRI-Unit, Suez Canal University Hospi-
tal from June 2009 to July 2010.
2.1. Inclusion criteria of case group
 Age more than 18 years.
 Previously diagnosed patients with chronic viral hepatitis
on basis of clinical history, results of PCR for HCV, liver
function tests, and indicated for percutaneous liver
biopsy.2.2. Exclusion criteria of case group
 Contraindication to liver biopsy (abnormal bleeding
proﬁle,. . .).
 Absolute contraindication to MR imaging.
 Patients refusing imaging by MR after fully explaining the
nature of the examination to them.2.3. Inclusion criteria of control group
 Age more than 18 years.
 Patients without history of chronic or acute liver disease on
basis of clinical history, results of liver function tests.2.4. Exclusion criteria of control group
 Patients with abnormal liver function tests.
 Patients refusing imaging by MR after fully explaining the
nature of the examination to them.
 Absolute contraindication to MR imaging.
All subjects in both groups were examined by 1.5 Tesla MR
scanner (Philips Medical Systems, Achieva); after preparatory
phase that includes the following:
2.5. History and laboratory examinations (PCR for HCV and
liver function tests)
2.5.1. Percutaneous liver biopsy
Ten days before DWI, patients with chronic viral hepatitis
were subjected to blinded percutaneous liver biopsy by an
experienced hepatologist using 18–20-gauge needle without
sonographic guidance. The liver biopsies ﬁndings were evalu-
ated by the two experienced pathologist in separate secessions.
2.5.2. Diffusion-weighted imaging protocol
The DW images were obtained by using single-shot echo-
planar imaging sequence that performed with a phased
array superﬁcial body coil with free breathing and ﬁnger
triggering pulse in a single acquisition using the following
parameters:
 Scan time: 6 min.
 TR:1300 m/s.
 TE: 70–86 m/s.
 Field of view: 320–400 mm.
 Slice thickness: 7 mm.
 Number of signals averaged: 2.
 Matrix: 192 · 256.
 Voxel size: 2.05 and 2.45.
 Diffusion gradient encoding in three orthogonal directions
at b values of (300, 500, 700, and 1000 s/mm2).
2.5.3. Post-processing of ADC maps
 Was performed by using dedicated standard software on a
workstation to obtain ADC maps for each b value.
 Regions of interest (ROIs) were measured in the same loca-
tions for all b values.
 The ADC value were measured in the lateral and medial
segments of the left lobe, and the anterior and posterior
Diagnostic value of apparent diffusion coefﬁcient 121segments of the right lobe in locations away from normal
intrahepatic vasculature and focal liver lesions.
 The ﬁnal ADC is the average of the four ROIs.Mean ADC (b=300)
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following as in patient’s group
1. History and laboratory examination (PCR for HCV and
liver function tests).
2. The diffusion-weighted (DW) images.
3. Post-processing of ADC maps.
2.6. Data analysis
To obtain diagnostic values of the hepatic ADC, we mea-
sured (sensitivity, speciﬁcity, positive, and negative predictive
values) of the analyzed data using commercially available
PC-based software package (SPSS), receiver operating char-
acteristic curve analysis (ROC), in comparative relation to
the liver biopsy ﬁndings and the normal subjects in control
group.
Ethical considerations This work have been carried out in
accordance with The Code of Ethics of the World Medical
Association. . ... An informed consent was taken from all the
participants before taking any data or doing any investigations
or imaging techniques.Figure 1 Represents ROC curve analysis; predictive ability of
mean hepatic ADC for stages PF3 versus 6F2 (at b-
value = 300 s/mm2). However, the best cut off value of mean
hepatic ADC to detect higher stage of ﬁbrosis (at b-value = 500 s/
mm2) is 61.67 with 84% sensitivity (95% CI = 72.6–99.1) and
82% speciﬁcity (95% CI = 78.8–96.1); Figs. 5 and 6.3. Results
A total of eligible 38 chronic viral hepatitis C patients with
similar normal control ones were subjected for this work. In
patient group; 24 males (61.8%), and 14 females (38.2%) Their
ages range between 20 and 57 years old with a mean age
(31.9 ± 5.7 years) The normal 38 subjects in control group;
28 males (73.6%) and 10 females (26.4%) and the subjects
were found in age group between 20 and 50 years old with a
mean age (31.8 ± 5.3 years).
The subjected patients underwent liver biopsy and staged
based upon Ishak Scoring System; including 10 patients in
F1; 10 patients in F2; six patients in F3; six patients in F4, ﬁve
patients in F5; and one patient in F6.
With nearby liver ﬁbrosis stages, based upon the b-values
ﬁgured in our study; two sub-groups were evoked; F1 and
F2 stages in the ﬁrst sub-group which represents 20 patients
(52.6%) and F3–F6 in the second one which represents 18
patients (47.4%).Table 1 Distribution of hepatic ADC (value · 103 mm2/s) stratiﬁe
b-Value (s/mm2)
(b= 300) (b= 500)
Control group 2.8 ± 0.3 2.1 ± 0.08
F1 2.2 ± 0.3 1.8 ± 0.08
F2 1.9 ± 0.04 1.7 ± 0.14
F3 1.8 ± 0.04 1.6 ± 0.2
F4 1.6 ± 0.1 1.4 ± 0.13
F5 1.1 ± 0.05 1.03 ± 0.04
F6 0.89 ± 0 0.9 ± 03.1. Mean hepatic ADC and ﬁbrosis stage
All eligible subjects including (patient and control groups);
underwent diffusion-weighted MRI of the liver, further ADC
map processing with mean hepatic ADC were measured at
four different b-values (300, 500, 700, and 1000 s/mm2).d by ﬁbrosis stages and subjects of control group.
p-Value
(b= 700) (b= 1000)
1.8 ± 0.03 1.5 ± 0.04 0.001*
1.7 ± 0.04 1.4 ± 0.07 0.001*
1.6 ± 0.09 1.3 ± 0.08 0.001*
1.4 ± 0.2 1.2 ± 0.07 0.001*
1.3 ± 0.13 1.1 ± 0.09 0.001*
0.9 ± 0.02 0.9 ± 0.08 0.001*
0.8 ± 0 0.8 ± 0 NS
Mean ADC (b=700)
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122 H.R. Ibrahim et al.The study evokes that; there is a trend toward a decrease in
mean hepatic ADC with increasing stage of liver ﬁbrosis. Also
there is signiﬁcant difference between control group and pa-
tient group with different liver ﬁbrosis stages. This is noted
at all examined b-values (p< 0.001).
However, values of mean hepatic ADC were seen insigniﬁ-
cant in stage F6 as there is only one patient examined in our
study (Table 1).
3.2. Mean hepatic ADC performance; ROC analysis
ROC curve analysis used to evaluate mean hepatic ADCperfor-
mance in prediction of stages>F3 versus<F2 ﬁbrosis stages at
different four b-values (300, 500, 700, and 1000 s/mm2).
It shows that best cut off value of mean hepatic ADC to de-
tect higher stage of ﬁbrosis (at b-value = 300 s/mm2) is 61.89
with 90% sensitivity (95% CI = 81.3–100) and 89% speciﬁcity
(95% CI = 88.1–99.5); Fig. 1.
However, the best cut off value of mean hepatic ADC to de-
tect higher stage of ﬁbrosis (at b-value = 500 s/mm2) is 61.67Mean ADC (b=500)
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Figure 2 Represents ROC curve analysis; predictive ability of
mean hepatic ADC for stages PF3 versus 6F2 (at b-
value = 500 s/mm2). Meanwhile, the best cut off value of mean
hepatic ADC to detect higher stage of ﬁbrosis (at b-value = 700 s/
mm2) is 61.63 with 87% sensitivity (95% CI = 72.6–99.1) and
85% speciﬁcity (95% CI = 88.1–99.5); Figs. 5–7.
Figure 3 Represents ROC curve analysis; predictive ability of
mean hepatic ADC for stages PF3 versus 6F2 (at b-
value = 700 s/mm2).with 84% sensitivity (95% CI = 72.6–99.1) and 82% speciﬁc-
ity (95% CI = 78.8–96.1); Fig. 2.
Meanwhile, the best cut off value of mean hepatic ADC to
detect higher stage of ﬁbrosis (at b-value = 700 s/mm2) is
61.63 with 87% sensitivity (95% CI = 72.6–99.1) and 85%
speciﬁcity (95% CI = 88.1–99.5); Fig. 3.
Finally, the best cut off value of mean hepatic ADC to de-
tect higher stage of ﬁbrosis (at b-value = 1000 s/mm2) is 61.3
with 89% sensitivity (95% CI = 81.3–100) and 88% speciﬁcity
(95% CI = 77–95); Fig. 4.
4. Discussion
Preliminary experience using diffusion-weighted MR imaging
and ADC measurement for quantiﬁcation of liver ﬁbrosis
was reported in few series; as in (3,19,20) and Zhu et al. (2009).
Our patient’s group (38 patients) underwent liver biopsy
and staged according to Ishak scoring system (10) patients in
stage F1, (10) patients in stage F2, (six) patients in stage F3,
(six) patients in stage F4, (ﬁve) patients in stage F5 and
(one) patient in stage F6).
In a study done by (3); to evaluate preliminary experience
using diffusion-weighted MRI for quantiﬁcation of liver ﬁbro-
sis. It included 23 patients with chronic hepatitis and seven
Mean ADC (b=1000)
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Figure 4 Represents ROC curve analysis; predictive ability of
mean hepatic ADC for stages PF3 versus 6F2 (at b-
value = 1000 s/mm2).
Diagnostic value of apparent diffusion coefﬁcient 123healthy volunteers. Nineteen patients with chronic hepatitis
underwent liver biopsy and staged according to Batts’s scoring
system (four patients in stage F0, ﬁve patients in stage F1, four
patients in stage F2, four patients in stage F3, and two patients
in stage F4), the remaining four patients with cirrhosis in-
cluded in the study diagnosed on the basis of clinical history
and imaging ﬁndings.
There is a point of difference between Taouli et al. and our
study concerning methodology; that all patients included in
our study underwent liver biopsy.
Also, unlike a study by Taouli et al., patients in stage F0
ﬁbrosis were not included in our study, as they are not indi-
cated for liver biopsy. Also, mean age of patients and demo-
graphic data differs to a small extent, but it has no effect on
the concept of research and ADC performance.
In another larger study done by (21); which evaluated the
clinical practical value of apparent diffusion coefﬁcient
(ADC) measurements based on diffusion-weighted MR imag-
ing (DWI) for quantiﬁcation of liver ﬁbrosis. Eighty-ﬁve pa-
tients with chronic hepatitis (50 patients with chronic
hepatitis C virus infection and 45 patients with chronic hepati-
tis B virus infection), and 22 healthy volunteers.
All patients underwent liver biopsy and staged according to
METAVIR scoring system (15 patients in stage F0, 27 patientsin stage F1, 23 patient in stage F2, 12 patients in stage F3, and
eight patients in stage F4).
Few differences had been observed between our study
and Zhou et al. study present in the form of smaller number
of patients included in our study. Also, involvement of pa-
tients with chronic hepatitis virus C infection only versus
involvement of both chronic viral C and B infected patients,
respectively.
In (21) series Diffusion-weighted MRI was prospectively
performed with (a time of delay of 60–90 days, between liver
biopsy and diffusion-weighted imaging; in patient’s group).
It was performed for all subjects (patients and healthy vol-
unteers) by using a single-shot spin-echo echo-planar se-
quence at b values of 100, 300, 500, 800, and 1000 s/mm2
respectively.
In Taouli et al., Diffusion-weighted MRI was done for all
subjects (with a mean time of delay of 42 days after biopsy),
using single-shot echo-planar sequence at b values of 50, 300,
500, 700, and 1000 s/mm2. The apparent diffusion coefﬁcient
(ADC) was measured.
In our series, low b-values as 50 and 100 s/mm2 were not
used to avoid perfusion contamination and to obtain reliable
measurements of ADC. Also, timing of diffusion-weighted
imaging and ADC measurement was standardized as 10 days
after biopsy to avoid any change in ﬁbrosis stage or any treat-
ment intervention effects.
There is an overall agreement between the previous studies
and ours where we all found that there was a trend toward a
decrease in mean hepatic ADC with increasing degree of ﬁbro-
sis; in which the mean hepatic ADC value of patients was sig-
niﬁcantly lower than that of healthy control.
This ﬁnding could be explained by a restricted motion of
water molecules in liver tissue in case of liver ﬁbrosis; as with
increasing degree of ﬁbrosis, more accumulation of extracellu-
lar proteins, larger amount of connective tissue, narrowed
sinusoids and reduced blood ﬂow and so more restricted mo-
tion of water molecules and subsequent decreased values of
mean hepatic ADC; which is a reﬂection of water molecules
diffusion.
The signiﬁcant negative correlation between mean hepatic
ADC and ﬁbrosis stage was observed for all used b values
(p= 0.001), except for stage F6 as only one patient was in-
cluded in our series.
For all b-values, signiﬁcant differences were observed be-
tween control group subjects and stage F1 ﬁbrosis also, be-
tween stage F2 and stage F3 ﬁbrosis, between stage F4 and
stage F5 ﬁbrosis, and between stage F5 and stage F6
ﬁbrosis.
The signiﬁcant differences observed between stage F1 and
stage F2 ﬁbrosis only for b values of 300 and 700 s/mm2), how-
ever, signiﬁcant differences between stage F3 and stage F4
ﬁbrosis seen only for b values of 300 and 500 s/mm2.
So, the comparison of ADCs between stages stratiﬁed
according to individual ﬁbrosis stage did not show great differ-
ences in between; as stage F1 versus stage F2 and stage F3 ver-
sus stage F4, as described previously.
The more comparative observation was the signiﬁcant de-
crease in mean hepatic ADC in patients with stagePF3 versus
stage 6F2 ﬁbrosis (p= 0.001) for all b-values.
So, ADC can perform well in differentiating patients into
two subgroups (patients with stage PF3 versus stage 6F2
ﬁbrosis), and according to the current treatment strategy
124 H.R. Ibrahim et al.depending on this differentiation, further searching for a cutoff
points between two subgroups will be helpful. This was a point
of study in this work and ROC curve analysis was used to
achieve it.
By using ROC curve analysis, we found mean hepatic ADC
to be a signiﬁcant predictor for stage PF3 versus stage 6F2
ﬁbrosis; as follows:
 At b value of 300 s/mm2, we found that a mean hepatic
ADC of 1.89 · 103 mm2/s or less perform well in predic-
tion and differentiation between previously mentioned sub-
groups; with a sensitivity of 90%, speciﬁcity of 89%,
positive predictive value of 90% and negative predictive
value of 93%.
 At b value of 500 s/mm2, we found that a mean hepatic
ADC of 1.67 · 103 mm2/s or less perform well in predic-
tion and differentiation between previously mentioned sub-
groups; with a sensitivity of 84%, speciﬁcity of 82%,
positive predictive value of 74% and negative predictive
value of 90%.
 At b value of 700 s/mm2, we found that a mean hepatic
ADC of 1.63 · 103 mm2/s or less perform well in predic-
tion and differentiation between previously mentioned sub-
groups; with a sensitivity of 87%, speciﬁcity of 85%,
positive predictive value of 90% and negative predictive
value of 90%.
 At b value of 1000 s/mm2, we found that a mean hepatic
ADC of 1.3 · 103 mm2/s or less perform well in prediction
and differentiation between previously mentioned sub-
groups; with a sensitivity of 89%, speciﬁcity of 88%, posi-
tive predictive value of 72% and negative predictive value
of 90%.
So, the best correlation seen at b values 300, 700, and
1000 s/mm2, which showed appropriate sensitivity, speciﬁcity,
positive, and negative predictive values, with lesser correlation
were obtained at b values of 500 s/mm2.
In a study done by (20); receiver operating characteristic
(ROC) analysis demonstrated a mean hepatic ADC cutoff of
1.31 · 103 mm2/s, with (sensitivity of 92.9% and speciﬁcity
of 100%, positive predictive value of 100%, negative predictive
value of 99.9%, and overall accuracy of 96.4%).
We share the concept of decreased mean hepatic ADC with
liver ﬁbrosis, but in Girometti et al. study, higher sensitivity,
speciﬁcity and over all accuracy resulting from that the com-
parison was done between the two extremes; which are normal
healthy controls and cirrhotic patients, respectively, so a signif-
icant difference must be present even in other imaging
modalities.
Finally, in comparing with the previously mentioned stud-
ies, few points of differences were elicited. In our study, one
group of chronic hepatitis was involved which is chronic hep-
atitis virus C infected persons, short time of delay (10 days) be-
tween biopsy and diffusion-weighted magnetic resonance
imaging, to obtain a more reliable ADC measurement, and
smaller number of subjected population. Also, low b-values
were not examined in our study to avoid perfusion
contamination.
Our study had some limitations, ﬁrstly; we reporting our
initial experience. Secondly; our results were limited by
small sample size, in particular the small number of pa-
tients with intermediate levels of hepatic ﬁbrosis, also stageF0 and F6 ﬁbrosis were not indicated for liver biopsy and
not involved in the study; except for one patient with stage
F6 ﬁbrosis.
In conclusion, we share points of correlation with the pre-
viously compared studies; that hepatic ADC measured with
DWI can serve as a promising tool; as a non-invasive tech-
nique for quantiﬁcation of liver ﬁbrosis, and could replace liver
biopsy; which has many complications and even death. It was
observed that mean hepatic ADC measurement can perform
well in differentiating stage 6F2 andPF3 by appropriate sen-
sitivity and speciﬁcity, and this observation was promising;
especially that the current treatment strategy that depending
on a cut point between stratiﬁed groups of patients with stages
6F2 and PF3 ﬁbrosis. Also, DWI can be easily incorporated
into a routine MRI protocol.
Although, these results in our series and the other
literatures are promising, future studies with a larger number
of patients are needed to improve the statistical power of the
current observation, since only studies in relatively small
number of patients have been performed in selected
population.
Also, further work was needed, to investigate DWI ﬁndings
and ADC measurements in new areas as in follow-up pro-
grams to assess patient response to treatment. Also, to corre-
late it with ﬁndings obtained with newer methods of
perfusion MRI, and MR elastography, and more assessment
of diffusion-weighted MRI to be addressed for the evaluation
of chronic liver disease, especially if newer treatment strategies
depending on individual stage of ﬁbrosis will be applied, before
it can be utilized in clinical practice.
Appendix A. Case (1)
A 30 years old male with the following data:
 No history of HCV infection.
 Normal level of liver enzymes.
i. AST measured 30 U/L.
ii. ALT measured 32 U/L. No liver biopsy was taken as the subject categorized in con-
trol group.
A.1. ADC ﬁndings
b-Value (s/mm2) Mean ADC · 103
b-Value = 1000 1.5
b-Value = 700 1.8
b-Value = 500 2.1
b-Value = 300 2.9
b-Value = (300–1000) 2.07A.2. Selected photos comments
1. Diffusion-weighted imaging and ADC values; (A) diffu-
sion-weighted MR imaging with b-value of 1000 s/mm2.
(B) Corresponding ADC map of the abdomen shows that
the liver has a mean ADC of 1.5 · 103 mm2/s.
2. Diffusion-weighted imaging and ADC values; (A) diffu-
sion-weighted MR imaging with b-value of 700 s/mm2.
(B) Corresponding ADC map of the abdomen shows that
the liver has a mean ADC of 1.8 · 103 mm2/s.
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Diagnostic value of apparent diffusion coefﬁcient 1273. Diffusion-weighted imaging and ADC values; (A) diffu-
sion-weighted MR imaging with b-value of 500 s/mm2.
(B) Corresponding ADC map of the abdomen shows that
the liver has a mean ADC of 2.1 · 103 mm2/s.
4. Diffusion-weighted imaging and ADC values; (A) diffu-
sion-weighted MR imaging with b-value of 300 s/mm2.
(B) Corresponding ADC map of the abdomen shows that
the liver has a mean ADC of 2.9 · 103 mm2/s.
Appendix B. Case (2)
A 39 years old male with the following data:
 History of HCV infection: evidence of +V anti-HCV anti-
bodies and moderate viral load on PCR (15 · 103 IU/ml).
 Normal level of liver enzymes:
i. AST measured 27 U/L.
ii. ALT measured 30 U/L. Liver biopsy ﬁndings: stage 3/6 ﬁbrosis (F3).B.1. ADC ﬁndings
b-Value (sec/mm2) Mean ADC · 103
b-Value = 1000 1.2
b-Value = 700 1.3
b-Value = 500 1.48
b-Value = 300 1.78
b-Value = (300–1000) 1.44B.2. Selected photos comments1. Diffusion-weighted imaging and ADC values; (A) diffu-
sion-weighted MR imaging with b-value of 1000 s/mm2.
(B) Corresponding ADC map of the abdomen shows that
the liver has a mean ADC of 1.2 · 103 mm2/s.
2. Diffusion-weighted imaging and ADC values; (A) diffu-
sion-weighted MR imaging with b-value of 700 s/mm2.
(B) Corresponding ADC map of the abdomen, shows that
the liver has a mean ADC of 1.3 · 103 mm2/s.
128 H.R. Ibrahim et al.
Diagnostic value of apparent diffusion coefﬁcient 129
130 H.R. Ibrahim et al.3. Diffusion-weighted imaging and ADC values; (A) diffu-
sion-weighted MR imaging with b-value of 500 s/mm2.
(B) Corresponding ADC map of the abdomen shows that
the liver has a mean ADC of 1.48 · 103 mm2/s.
4. Diffusion-weighted imaging and ADC values; (A) diffu-
sion-weighted MR imaging with b-value of 300 s/mm2.
(B) Corresponding ADC map of the abdomen shows that
the liver has a mean ADC of 1.78 · 103 mm2.
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